Role of Adjuvant Chemotherapy in Distal Cholangiocarcinoma
October 31, 2024 updated by: Seoul National University Hospital
Role of Adjuvant Chemotherapy in Distal Cholangiocarcinoma: a Retrospective Cohort Study
Recent studies addressing the role of adjuvant chemotherapy in cholangiocarcinoma (CCA) have been published; however, there are challenges in generalizing the findings due to different prognostic characteristics depending on tumor location and resectability.
Therefore, the aim of this study was to investigate the role of AC in distal cholangiocarcinoma, a common tumor subtype of CCA.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
578
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patient with distal cholangiocarcinoma who underwent curative surgery
Description
Inclusion Criteria:
- Patients with distal cholangiocarcinoma who underwent surgery
Exclusion Criteria:
- Who underwent neoadjuvant treatment
- Who underwent R2 resection
- Non-adenocarcinoma patients in final pathology report
- Insufficient data
- Death within 90days of surgery
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Role of Adjuvant Chemotherapy in Distal Cholangiocarcinoma
Time Frame: From January 2000 to December 2021
|
From January 2000 to December 2021
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2000
Primary Completion (Actual)
December 31, 2021
Study Completion (Actual)
October 1, 2024
Study Registration Dates
First Submitted
October 31, 2024
First Submitted That Met QC Criteria
October 31, 2024
First Posted (Estimated)
November 4, 2024
Study Record Updates
Last Update Posted (Estimated)
November 4, 2024
Last Update Submitted That Met QC Criteria
October 31, 2024
Last Verified
October 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2408-168-1565
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.